ClinicalTrials.gg

Program

sivopixant

Also written as “Sivopixant” and “S-600918”.

Its studies are mostly in Sleep Apnea Syndromes · Chronic Cough, led by Shionogi.

Furthest: phase 2, since Sep 26, 20192 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shionogi21 open or runningphase 2since Sep 26, 2019Sep 26, 2019Dec 31, 2026phase 2 · NCT06776432

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 26, 2019First study: phase 2 study in Chronic CoughFirst studyNCT04110054 · 406 enrolled · United States, Czechia, Japan and more
  2. Jan 3, 2025Phase 2 study in Sleep Apnea SyndromesNCT06776432 · 60 enrolled · United States

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Sleep Apnea SyndromesNCT06776432

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06776432Sleep Apnea Syndromes · United States2Active, not recruitingDec 31, 202660
NCT04110054Chronic Cough · United States, Czechia, Japan and more2CompletedDec 8, 2020406

How it is read

Names in the registry

  • “Sivopixant”, 1 entry
  • “S-600918”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
sivopixant (Shionogi): development program | ClinicalTrials.gg